Insmed Q2 revenue beats estimates

Insmed Incorporated

06/08/2026 12:21

Overview
U.S. biopharma firm's Q2 revenue rose sharply, beating analyst expectations
Net loss narrowed to $13.2 mln from $321.7 mln a year earlier
Company raised 2026 BRINSUPRI revenue guidance and updated peak sales estimates

Outlook
Company raises 2026 BRINSUPRI revenue guidance to $1.25 bln-$1.40 bln
Insmed reiterates 2026 ARIKAYCE revenue guidance of $450 mln-$470 mln
Company raises peak revenue estimate for its three lead programs to more than $14 bln

Result Drivers
BRINSUPRI LAUNCH - Q2 revenue growth was driven by strong uptake of BRINSUPRI in the U.S., with sales rising 49% over Q1
ARIKAYCE INTERNATIONAL GROWTH - ARIKAYCE revenue increased 8% year-over-year, mainly due to growth in international markets
LOWER COST OF SALES RATIO - Cost of product revenues as a percentage of revenue decreased due to BRINSUPRI's lower manufacturing costs

Company press release: ID:nPn6mflpDa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$425.50 mln
$392.84 mln (18 Analysts)
Q2 Loss Per Share
 
$0.06
 
Q2 Net Loss
 
$13.20 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Insmed Inc is $198.11, about 100.1% above its August 5 closing price of $99.02

Reuters Recommended Reads
Aug 5 - BioCryst Pharmaceuticals Q2 revenue rises, lifts 2026 revenue guidance
Aug 5 - Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Aug 3 - Curium strikes up to $8 bln deal for radiopharma peer Lantheus

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)